PRESS RELEASE
from Fresenius Medical Care AG & Co. KGaA (isin : DE0005785802)
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA confirms review of the deconsolidation and a potential change of the legal form into a German stock corporation
EQS-Ad-hoc: Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous
Fresenius Medical Care AG & Co. KGaA confirms review of the deconsolidation and a potential change of the legal form into a German stock corporation
09-Feb-2023 / 16:26 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Bad Homburg, February 9, 2023
Following press reports, Fresenius Medical Care AG & Co. KGaA (“Company”) confirms that Fresenius SE & Co. KGaA, which is holding approx. 32% of the shares of the Company and which is the sole shareholder of the general partner Fresenius Medical Care Management AG, is reviewing the deconsolidation of the Company. This review includes a potential change of the legal form of the Company into a German stock corporation (Aktiengesellschaft). The review of the required measures by the Company continues and the necessary decisions of the competent bodies are still outstanding. It therefore remains open whether a deconsolidation and a change of the legal form will occur. Contact:
Dr. Dominik Heger
EVP | Head of Investor Relations, Strategic Development & Communications
dominik.heger@fmc-ag.com
P. +49 6172 609 2601
Following press reports, Fresenius Medical Care AG & Co. KGaA (“Company”) confirms that Fresenius SE & Co. KGaA, which is holding approx. 32% of the shares of the Company and which is the sole shareholder of the general partner Fresenius Medical Care Management AG, is reviewing the deconsolidation of the Company. This review includes a potential change of the legal form of the Company into a German stock corporation (Aktiengesellschaft). The review of the required measures by the Company continues and the necessary decisions of the competent bodies are still outstanding. It therefore remains open whether a deconsolidation and a change of the legal form will occur.
Dr. Dominik Heger
EVP | Head of Investor Relations, Strategic Development & Communications
dominik.heger@fmc-ag.com
P. +49 6172 609 2601
09-Feb-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Fresenius Medical Care AG & Co. KGaA |
| Else-Kröner-Straße 1 | |
| 61352 Bad Homburg | |
| Germany | |
| Phone: | +49 (0) 6172- 609 2525 |
| Fax: | +49 (0) 6172- 609 2301 |
| E-mail: | ir@fmc-ag.com |
| Internet: | www.freseniusmedicalcare.com |
| ISIN: | DE0005785802 |
| WKN: | 578580 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange |
| EQS News ID: | 1556373 |
| End of Announcement | EQS News Service |
1556373 09-Feb-2023 CET/CEST